Penpulimab Combined With GP ± Anlotinib as Neoadjuvant Therapy in Locoregionally Advanced Nasopharyngeal Carcinoma

StatusActive, Not Recruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 9 months later Jan 1, 2025 → Oct 1, 2026
See other at-risk trials from Sun Yat-sen University

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Jan 1, 2025 to Oct 1, 2026 Show 6 more changesShow less
    • Start date: Jan 20, 2022 to Aug 17, 2022
    • Study completion pushed from Jan 1, 2027 to Oct 1, 2028
    • Enrollment target: estimated 104 to confirmed 105
    • Eligibility criteria expanded, about 24 words
    • Secondary endpoints: details revised at 2 of 5 entries
    • Publications: details revised at 2 of 2 entries
  2. Primary completion date: Jan 1, 2024 to Jan 1, 2025v2 Show 5 more changesShow less
    • Trial status: Not Yet Recruiting to Active, Not Recruiting
    • Study sites: 0 to 1
    • Interventions: GP+Peramprizumab (Drug), GP+Peramprizumab+Anlotinib (Drug) to GP+Penpulimab (Drug), GP+Penpulimab+Anlotinib (Drug)
    • Study description revised
    • Study title revised
  3. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
The purpose of this study is to explore the efficacy and safety of a combination of GP chemotherapy and Penpulimab ± Anlotinib in neoadjuvant therapy combined with Penpulimab in adjuvant therapy of locoregionally advanced nasopharyngeal carcinoma patients.
Trial Details
NCT Number NCT05193617
Lead Sponsor Sun Yat-sen University
Conditions
(from sponsor)		 Nasopharyngeal Carcinoma
Related terms Nasopharyngeal Carcinoma
Enrollment 105 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov